Olainfarm will hold First Quarter 2017 Investor Conference Webinar

Olaine, 2017-06-20 15:32 CEST (GLOBE NEWSWIRE) -- presentation will be held in English. During the webinar Salvis Lapiņš will inform about AS “Olainfarm” latest activities and analyze the financial results of the first quarter 2017. After the presentation investors are welcome to ask questions. Due to the limited webinar time, please send in your questions in advance … [Read more...]

Share buy-back week 24/2017

Announcement              19 June 2017   Coloplast – transactions in connection with share buy-back programme  As mentioned in Announcement No. 2/2017 Coloplast has initiated the second part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to … [Read more...]

Invitation Coloplast Meet the Management Event 2017

We would like to invite you to participate in Coloplast’s Meet the Management Event in London on Friday 18 August 2017 at 10:30-17:30 At Andaz London Liverpool Street 40 Liverpool Street London EC2M 7QN, United Kingdom   The purpose of the event is to provide institutional investors and financial analysts with the opportunity to meet Lars Rasmussen, President … [Read more...]

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor Genmab to receive milestone payments totaling USD 25 million Copenhagen, Denmark; June 16, 2017 – Genmab A/S (Nasdaq … [Read more...]

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

Company Announcement Preliminary data shows responses achieved in 11 of 34 evaluable patients with cervical cancer treated with tisotumab vedotin Next steps in clinical development of tisotumab vedotin in this indication under active consideration Copenhagen, Denmark; June 16, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today preliminary data from the … [Read more...]